TuHURA Biosciences, Inc. Common Stock
Symbol: HURA (NASDAQ)
0.00
▼ (-100.00%) -2.370
Company Description:
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Key Stats
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $2.37
- Yesterday High: $2.4591
- Yesterday Low: $2.32
- Yesterday Volume: 267.14K
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
Company Profile
- Name: TuHURA Biosciences, Inc. Common Stock
- Website: https://www.tuhurabio.com
- Listed Date: 2024-10-18
- Location: TAMPA, FL
- Market Status: Active
- CIK Number: 0001498382
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $126.12M
- Round Lot: 100
- Outstanding Shares: 50.05M
- Asset Type: CS
RECENT FILINGS FOR HURA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-14 | 8-K | View |
| 2025-08-12 | S-1 | View |
| 2025-08-12 | 8-K/A | View |
| 2025-07-29 | SCHEDULE 13G | View |
| 2025-06-30 | 8-K | View |
| 2025-06-27 | 8-K | View |
| 2025-06-24 | 425 | View |
| 2025-06-24 | 8-K | View |
| 2025-06-13 | D | View |
| 2025-06-12 | 8-K | View |
| 2025-06-06 | 425 | View |
| 2025-06-06 | 8-K | View |
| 2025-06-03 | 425 | View |
| 2025-05-23 | ARS | View |
| 2025-05-23 | 424B3 | View |
| 2025-05-15 | 10-Q | View |
| 2025-05-15 | 425 | View |
Latest News on HURA